Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Relief Therapeutics' Lead Candidate Gets US Orphan Drug Tag In Sarcoidosis

Author: Vandana Singh | August 03, 2021 06:34am

The FDA has granted Orphan Drug Designation to Relief Therapeutics Holding AG's (OTC:RLFTF) for RLF-100 (aviptadil), an inhaled formulation, for sarcoidosis.
RLF-100 is a synthetic form of vasoactive intestinal peptide.
Sarcoidosis is a rare disease in which the inflammatory process involves the alveoli (air sacs), small bronchi, and small blood vessels.
RLF-100 is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.
Price Action: RLFTF shares closed at $0.24 on Monday.
Related content: Benzinga's Full FDA Calendar.

Posted In: RLFTF